Crystal Pharma
http://www.crystalpharma.co.in
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Crystal Pharma
Zydus Q1: Novel Molecule Enters Phase I, Global Biosimilar Strategy To Shift?
Zydus has begun Phase I trials for an anti-properdin drug in India while its sitagliptin franchise in US, distinct from Merck’s Januvia and Janumet, looks promising. Meanwhile MD Sharvil Patel says a biosimilars entry in developed markets is possible if certain conditions are met.
Zydus Q1: Novel Molecule Enters Phase I, Global Biosimilar Strategy To Shift?
Zydus has begun Phase I trials for an anti-properdin drug in India while its sitagliptin franchise in US, distinct from Merck’s Januvia and Janumet, looks promising. Meanwhile MD Sharvil Patel says a biosimilars entry in developed markets is possible if certain conditions are met.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice